Posted by Site Administrator on May 4, 2013
“That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial.”
Categories: ALS Community News, ALS Families, ALS News, Clinical Trials, Research News, Treatments
| 
Tags: ALS, ALS Awareness Month, ALS cell therapy, ALS clinical trial, ALS community, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Intraspinal Stem Cell Transplantation in ALS, Karl Johe, Lou Gehrig's disease, Neuralstem Incorporated, NSI-566 Phase I trial ALS, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| 
No comments
Posted by Site Administrator on March 1, 2013
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
From the UKMND-LiCALS Study Group
Summary article posted online in The Lancet Neurology, February 27, 2013 •
Background
Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a [...]
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS clinical trial, ALS medical care, ALS research, ALS research funding, ALS treatment research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, LiCALS trial, lithium ALS treatment, lithium carbonate, PALS, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, The Motor Neurone Disease Association of Great Britain and Northern Ireland
| No comments
Posted by Site Administrator on May 27, 2012
Company requesting permission to evaluate efficacy in its phase 1 safety trial, as well as to increase the dosage and number of trial participants.
Categories: 501(c)(3) Non-Profit, Research News, Treatments
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS clinical trial, ALS community, ALS research, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig’s disease, mortality ALS, Neuralstem, PALS, Phase 1 safety efficacy, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
